Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Aon (NYSE: AON) launched Resilience Quotient, a data-driven framework that combines Aon's Risk Capital and Human Capital analytics with Gallup World Poll sentiment data (covering 140 countries over 20+ years) to give a portfolio view of risk and resilience.
The tool maps how four megatrends—Trade, Technology, Weather and Workforce—compound risk, offers three case studies (data center growth with a $1.3 trillion 2030 data‑center investment projection, AI workforce transformation, and humanitarian finance for forced migration), and is delivered via a real-time, AI-enabled analytics platform built by Quantum Rise. Aon and Gallup will discuss the work at the World Economic Forum Annual Meeting.
Viatris (Nasdaq: VTRS) appointed Lara Ramsburg as Chief People and Corporate Affairs Officer effective Jan. 8, 2026. The newly combined role will align internal people functions with external corporate affairs to advance culture, stakeholder communication and sustainability priorities. Ramsburg brings more than 25 years of experience and has led Viatris corporate affairs since 2019, previously serving in the Office of the CEO and as Head of Integration. Responsibilities now include global talent, total rewards, employee experience, people solutions and HR business partners.
Viatris (Nasdaq: VTRS) reported four regulatory milestones across its global pipeline on Dec 18, 2025: FDA approval of a generic octreotide acetate injectable suspension (generic Sandostatin LAR Depot); FDA acceptance of an NDA for a low dose estrogen weekly contraceptive patch with a PDUFA date of July 30, 2026; FDA clearance of an IND for MR-146 AAV gene therapy with a planned Phase 1/2 CORVITA trial in H1 2026; and PMDA acceptance of a J-NDA for pitolisant in obstructive sleep apnea syndrome, with a J-NDA for narcolepsy still on track by year-end.
These items advance development and regulatory pathways across generics, women’s health, ophthalmology gene therapy, and sleep-disorder franchises.
Viatris (Nasdaq: VTRS) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026. The company's presentation and fireside chat begin at 9:00 a.m. PT / 12:00 p.m. ET. A live webcast will stream at investor.viatris.com, and an archived recording will be available at the same location for a limited time after the event.
Viatris (Nasdaq: VTRS) will participate in two investor conferences in early December 2025.
The company will take part in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 8:30 a.m. ET, and a fireside chat at the Evercore 8th Annual Healthcare Conference on December 3, 2025 at 8:45 a.m. ET. Both sessions will be available live and archived at investor.viatris.com for a limited time.
Viatris (Nasdaq: VTRS) announced it was named one of the Fortune World's Best Workplaces™ 2025 on November 13, 2025.
The list of 25 global leaders was selected from organizations that completed Great Place To Work’s employee survey, which gathered over 9 million responses representing more than 25 million employees. Eligibility required 5,000+ global employees and recognition on at least five regional Best Workplaces lists in 2024 or early 2025. Viatris highlighted employee feedback, wellbeing, inclusion, and its transformation since founding. The company pointed to related recognitions and its 2024 Sustainability Report for details on people and community initiatives.
Viatris (Nasdaq: VTRS) reported third-quarter 2025 results and updated full-year guidance on Nov 6, 2025.
Key Q3 metrics: Total revenues $3.76B (flat YoY), Adjusted EBITDA $1.155B (down 10% YoY), Adjusted EPS $0.67 (down 11% YoY), U.S. GAAP net loss $(128)M. The company generated $744.9M operating cash and $658.1M free cash flow in Q3.
Business updates include the acquisition of Aculys Pharma (pitolisant and Spydia rights in Japan/APAC), FDA approval of Iron Sucrose Injection, NDA submission for a low-dose estrogen weekly patch (expect mid-2026 approval), and >$920M returned to shareholders YTD including $500M in buybacks. Guidance ranges for 2025 revenues, adjusted EBITDA and adjusted EPS were raised and narrowed.
Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared by the board on November 3, 2025. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 24, 2025. This provides a concrete cash return timetable for VTRS shareholders.
Locus Biosciences announced a research collaboration with Viatris (NASDAQ: VTRS) on October 28, 2025 to develop precision engineered bacteriophage therapeutics for serious ophthalmic bacterial infections.
The collaboration will apply Locus’s platform—predictive AI, high-throughput robotics, and synthetic biology—to create bacteriophage cocktails aimed at selectively eliminating eye-pathogenic bacteria while sparing beneficial species. The program targets infections complicated by rising antibiotic resistance and seeks to advance phage-based alternatives or complements to traditional antibiotics.
Viatris (Nasdaq: VTRS) completed the acquisition of Aculys Pharma, acquiring exclusive Japan development and commercialization rights to pitolisant and exclusive Japan and select Asia‑Pacific rights to Spydia Nasal Spray.
Viatris said pitolisant showed strong Phase 3 results in Japanese patients and is on track for an MHLW marketing application for narcolepsy and OSAS-related daytime sleepiness by end of 2025. Spydia received approval in Japan in June 2025 for status epilepticus. Transaction consideration includes an upfront payment, contingent regulatory/commercial milestone payments, and royalties on net sales.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
